Harsimran Sachdeva Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harsimran Sachdeva Singh has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
Dmitriy N. Feldman
Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, New York
7 shared publications- Geoffrey Bergman
Department of Medicine, Division of Cardiology, Weill Cornell Medicine – New York Presbyterian Hospital, Weill Cornell Cardiovascular Outcomes Research Group (CORG) and the Greenberg Institute for Cardiac Electrophysiology, NY (E.V.R., C.F.L., S.C.W., G.B., J.E.I., G.T., S.M.M., B.B.L., L.K.K., J.W.C.).
7 shared publications Geoffrey Bergman
Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York, USA
5 shared publicationsRobert M. Minutello
Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, New York
5 shared publications- Robert M. Minutello
Division of Cardiology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA
5 shared publications S. Chiu Wong
5 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (36) , 109215
Pulmonary Arterial Hypertension With a Secundum Atrial Septal Defect
- 10 July 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (36) , 109215
Open AccessPulmonary Arterial Hypertension With a Secundum Atrial Septal Defect
- Open Access
- 8 January 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (3S) , S196-S204
The CHI-RON Study
Background: The Congenital Heart Initiative-Redefining Outcomes and Navigation to Adult-Centered Care (CHI-RON) study is a unique collaboration between the PCORnet and Congenital Heart Initiative (CHI), the first patient powered registry for adult congenital heart disease (ACHD) patients. The CHI-RON study examines the effects of gaps in recommended care in ACHD. Objective: Recruitment of racially diverse, younger, out-of-care, and male participants has been challenging in ACHD studies. Our goal was to design patient engagement and recruitment strategies to improve representation. Research Design: Launched in December 2020, patients from any location can self-enroll in the CHI registry, while the CHI-RON study (5/2022 – 10/2023) recruited ACHD patients at 12 sites participating in PCORnet. CHI-RON Recruitment methodology included a patient partner engagement toolkit and a recruitment algorithm using the PCORnet ® Common Data Model designed specifically to improve diversity and reduce self-enrollment biases in comparison to the CHI registry. Subjects: ACHD patients, age 18 years or older, with the ability to complete PROs independently. Measures: Demographic/Recruitment Statistics for study participants and Patient Engagement in Research Scale (PEIRS-22) for the study team partners. Results: As of October 2023, a total of 2652 participants were recruited through CHI-RON recruitment methodology while 1326 were self-enrolled in the CHI. CHI-RON recruitment methodologies have increased representation when compared with self-enrolled CHI participants in terms of ethnicity (10.9% vs. 7.4% Hispanic, P P P P P <0.001). Most study team patient partners (n=12, 86%) reported a very to extremely high degree of engagement (PEIRS-22 average score 101.6), especially in the subdomains of contributions, support, feeling valued, and benefits. Conclusions: Patient engagement and novel recruitment strategies are critical to improving the inclusion of under-represented populations in clinical research and ensuring alignment with the needs of ACHD patients.
- 8 January 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (3S) , S196-S204
Open AccessThe CHI-RON Study
Background: The Congenital Heart Initiative-Redefining Outcomes and Navigation to Adult-Centered Care (CHI-RON) study is a unique collaboration between the PCORnet and Congenital Heart Initiative (CHI), the first patient powered registry for adult congenital heart disease (ACHD) patients. The CHI-RON study examines the effects of gaps in recommended care in ACHD. Objective: Recruitment of racially diverse, younger, out-of-care, and male participants has been challenging in ACHD studies. Our goal was to design patient engagement and recruitment strategies to improve representation. Research Design: Launched in December 2020, patients from any location can self-enroll in the CHI registry, while the CHI-RON study (5/2022 – 10/2023) recruited ACHD patients at 12 sites participating in PCORnet. CHI-RON Recruitment methodology included a patient partner engagement toolkit and a recruitment algorithm using the PCORnet ® Common Data Model designed specifically to improve diversity and reduce self-enrollment biases in comparison to the CHI registry. Subjects: ACHD patients, age 18 years or older, with the ability to complete PROs independently. Measures: Demographic/Recruitment Statistics for study participants and Patient Engagement in Research Scale (PEIRS-22) for the study team partners. Results: As of October 2023, a total of 2652 participants were recruited through CHI-RON recruitment methodology while 1326 were self-enrolled in the CHI. CHI-RON recruitment methodologies have increased representation when compared with self-enrolled CHI participants in terms of ethnicity (10.9% vs. 7.4% Hispanic, P P P P P <0.001). Most study team patient partners (n=12, 86%) reported a very to extremely high degree of engagement (PEIRS-22 average score 101.6), especially in the subdomains of contributions, support, feeling valued, and benefits. Conclusions: Patient engagement and novel recruitment strategies are critical to improving the inclusion of under-represented populations in clinical research and ensuring alignment with the needs of ACHD patients.
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (1) , e016351
A New Beat: Tracing the Journey of Transcatheter Pulmonary Valve Replacement
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (1) , e016351
A New Beat: Tracing the Journey of Transcatheter Pulmonary Valve Replacement
- Open Access
- 19 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7757
Role of Antiplatelets and Anticoagulation Therapies in Pregnancy
Thrombosis is an important cause of morbidity and mortality worldwide. Pregnancy is a hypercoagulable state, and thrombotic complications in pregnancy are a major cause of maternal and fetal morbidity and mortality. Current guidelines support the selective use of aspirin, heparin, and warfarin in pregnant women. The decision to treat with antiplatelets and anticoagulants during pregnancy can be challenging, as these agents have numerous indications and contraindications, potential teratogenicity, and dosing considerations. Their use requires thoughtful discussion between patient and provider that balances therapeutic benefit versus maternal and fetal risks, while accounting for a safe delivery plan. Our aim is to provide a narrative review of the established and emerging indications of antiplatelets and anticoagulants, discuss their appropriate timing of administration, and consider their associated adverse fetal and maternal risks.
- 19 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7757
Open AccessRole of Antiplatelets and Anticoagulation Therapies in Pregnancy
Thrombosis is an important cause of morbidity and mortality worldwide. Pregnancy is a hypercoagulable state, and thrombotic complications in pregnancy are a major cause of maternal and fetal morbidity and mortality. Current guidelines support the selective use of aspirin, heparin, and warfarin in pregnant women. The decision to treat with antiplatelets and anticoagulants during pregnancy can be challenging, as these agents have numerous indications and contraindications, potential teratogenicity, and dosing considerations. Their use requires thoughtful discussion between patient and provider that balances therapeutic benefit versus maternal and fetal risks, while accounting for a safe delivery plan. Our aim is to provide a narrative review of the established and emerging indications of antiplatelets and anticoagulants, discuss their appropriate timing of administration, and consider their associated adverse fetal and maternal risks.
- Open Access
- 1 January 2024
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 19 (6) , 627-634
Climate Change and Congenital Heart Disease: A Narrative Review
Congenital Heart Disease (CHD) is the most common birth defect and a leading cause of infant morbidity and mortality worldwide. While genetic factors play a significant role in its development, up to 30% of CHD is associated ... | Find, read and cite all the research you need on Tech Science Press
- 1 January 2024
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 19 (6) , 627-634
Open AccessClimate Change and Congenital Heart Disease: A Narrative Review
Congenital Heart Disease (CHD) is the most common birth defect and a leading cause of infant morbidity and mortality worldwide. While genetic factors play a significant role in its development, up to 30% of CHD is associated ... | Find, read and cite all the research you need on Tech Science Press
- 30 July 2023
- Published by Springer Nature
- p. 139-154
Closure of Defects in the Muscular Ventricular Septum
- 30 July 2023
- Published by Springer Nature
- p. 139-154
Closure of Defects in the Muscular Ventricular Septum
- 1 January 2022
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 16 (1) , 1-10
How Technology Is Changing Interventional Cardiology
- 1 January 2022
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 16 (1) , 1-10
How Technology Is Changing Interventional Cardiology
- Open Access
- 20 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3701
Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis
The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014. We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy tended to be older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio (OR), 1.35; 95% confidence interval (CI), 1.18–1.56). Non-cardiac causes were the most common causes of readmission for TTS patients with malignancy versus without malignancy (75.5% vs. 68.1%, p < 0.001). The 30-day readmission rate due to recurrent TTS was very low in both groups (0.4% and 0.5%; p = 0.47). The total costs were higher by 25% (p < 0.001) in TTS patients with vs. without malignancy. In summary, among patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission and increased costs. These findings highlight the importance of optimized management for TTS patients with malignancy.
- 20 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3701
Open AccessThirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis
The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014. We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy tended to be older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio (OR), 1.35; 95% confidence interval (CI), 1.18–1.56). Non-cardiac causes were the most common causes of readmission for TTS patients with malignancy versus without malignancy (75.5% vs. 68.1%, p < 0.001). The 30-day readmission rate due to recurrent TTS was very low in both groups (0.4% and 0.5%; p = 0.47). The total costs were higher by 25% (p < 0.001) in TTS patients with vs. without malignancy. In summary, among patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission and increased costs. These findings highlight the importance of optimized management for TTS patients with malignancy.